Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIALTO interval trial of Lutathera every 8 versus 16 weeks in advanced midgut neuroendocrine tumors
2024-517921-14-00Phase 2Authorised
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Mar 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in midgut neuroendocrine tumor (MNET) (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Rate of grade 2-5 hematological toxicity. Planned start Mar 2025; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
midgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on 2024-517921-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517921-14-00.